Nexelis Acquires AIT Bioscience

Nexelis to Acquire ImmunXperts

April 4, 2020

Healthcare Services

Nexelis, a portfolio company of Ampersand Capital Partners, has signed a definitive agreement to acquire ImmunXperts, a specialty immunogenicity and immuno‑oncology testing laboratory based in Gosselies, Belgium. The add-on deal will expand Nexelis' assay development and immunology testing capabilities and is expected to close by the end of March 2020.

Q² Solutions (IQVIA) Acquires Nexelis from Ampersand Capital Partners

January 10, 2022

Healthcare Services

Ampersand Capital Partners sold its portfolio company Nexelis to Q² Solutions, a wholly owned subsidiary of IQVIA, Inc. Nexelis, a Laval, Quebec–based provider of assay development and advanced clinical-trial laboratory testing with five operating sites in North America and Europe, will be integrated into IQVIA's global laboratory services to expand capabilities and capacity for vaccine, immunology and other drug-development testing.

Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory (Marburg)

January 20, 2021

Biotechnology

Nexelis, a portfolio company of Ampersand Capital Partners, has signed an asset purchase agreement to acquire GSK's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany. Approximately 80 scientists and analysts will transfer to Nexelis, which also entered a five-year strategic collaboration with GSK to continue supporting vaccine development while expanding Nexelis' assay development and high-throughput clinical testing capabilities in Europe.

PerkinElmer Acquires Nexcelom Bioscience for $260M

May 13, 2021

Medical Devices

PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.

BioAgilytix Acquires 360biolabs and MicroConstants

October 14, 2021

Healthcare Services

BioAgilytix Labs, LLC acquired Australia-based 360biolabs and US-based MicroConstants to expand its global footprint and bioanalytical capabilities, including LC/MS/MS, virology and immunology expertise. The deals (360biolabs subject to FIRB approval) add capacity in Melbourne and Brisbane and establish BioAgilytix San Diego, strengthening support for first-in-human and early-phase clinical trials across major geographies.

Excelra Acquires BISC Global

April 19, 2023

Biotechnology

Excelra has acquired BISC Global, a consulting-led bioinformatics and data analytics services firm with offices in Europe and the US. The deal expands Excelra's AI/ML, bioinformatics and next-generation sequencing capabilities and combines complementary platforms and service offerings to accelerate drug discovery and development.